Skip to content
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Can Psilocybin Challenge Our Pharmaceutical Dependence?

Can Psilocybin Challenge Our Pharmaceutical Dependence?

  • Post author:Olly PP
  • Post published:October 12, 2022
  • Post category:Industry News
Tags: Home News, Industry Media

Read more articles

Previous PostThe Magic Mushroom Experience: Taking Psilocybin for Science
Next PostThe MHRA’s Innovation Passport

You Might Also Like

Read more about the article After Its Vilification In The 1960s, There Is Now A Renaissance In Psychedelic Drugs To Help Treat Depression And Mental Health Issues

After Its Vilification In The 1960s, There Is Now A Renaissance In Psychedelic Drugs To Help Treat Depression And Mental Health Issues

February 19, 2022
Read more about the article How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

June 11, 2022
Read more about the article Can ‘magic mushrooms’ and MDMA cure depression?

Can ‘magic mushrooms’ and MDMA cure depression?

June 22, 2022

Recent Posts

  • Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors
  • Albert Labs Management and Board of Director Announcement
  • Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement

Recent Comments

  • Randal Elliott on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Nicholas Stewart on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Camille Ortega on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Kelly Lambert on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Dean Phillips on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2024 Albert Labs. All Rights Reserved

  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact [email protected]

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

  • This field is for validation purposes and should be left unchanged.
Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok